Barclays raised the firm’s price target on Arvinas to $60 from $26 and keeps an Overweight rating on the shares post the Q4 report. The analyst cites expanded development plans with the company’s ER degrader and adding in BCL6 degrader and LRRK2 degrader into the model for the target increase.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Arvinas expects cash to fund operations into 2027
- Arvinas reports Q4 EPS ($2.53), consensus ($1.27)
- ARVN Earnings Report this Week: Is It a Buy, Ahead of Earnings?